Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis C, Chronic | 10 | 2020 | 973 | 1.70 | Why? |
| Hepatitis B, Chronic | 7 | 2019 | 616 | 1.65 | Why? |
| Hepatitis B | 9 | 2018 | 888 | 1.65 | Why? |
| Hepatitis C | 7 | 2020 | 1514 | 1.05 | Why? |
| Hepatitis B e Antigens | 3 | 2018 | 99 | 1.01 | Why? |
| HIV Infections | 22 | 2021 | 11620 | 0.97 | Why? |
| Hepatitis B virus | 9 | 2018 | 882 | 0.92 | Why? |
| Coinfection | 21 | 2020 | 6820 | 0.86 | Why? |
| Hepatitis B Surface Antigens | 4 | 2018 | 305 | 0.82 | Why? |
| Hepatitis, Viral, Human | 2 | 2020 | 196 | 0.74 | Why? |
| Hepatitis C Antigens | 1 | 2017 | 18 | 0.70 | Why? |
| Tenofovir | 3 | 2018 | 449 | 0.68 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.65 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.64 | Why? |
| Liver Cirrhosis | 6 | 2019 | 1810 | 0.62 | Why? |
| Immune Sera | 1 | 2020 | 884 | 0.61 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.60 | Why? |
| Hepatitis B Vaccines | 1 | 2017 | 245 | 0.59 | Why? |
| B-Lymphocytes | 5 | 2021 | 4418 | 0.55 | Why? |
| Disease Eradication | 2 | 2018 | 581 | 0.48 | Why? |
| Ribavirin | 3 | 2020 | 1182 | 0.46 | Why? |
| Lymphopenia | 2 | 2020 | 2669 | 0.45 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.45 | Why? |
| Substance Abuse, Intravenous | 3 | 2020 | 411 | 0.41 | Why? |
| Viral Core Proteins | 2 | 2018 | 134 | 0.35 | Why? |
| Antiviral Agents | 14 | 2021 | 41703 | 0.33 | Why? |
| Benzimidazoles | 2 | 2018 | 275 | 0.29 | Why? |
| Point-of-Care Testing | 1 | 2017 | 2782 | 0.27 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.27 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.27 | Why? |
| Sustained Virologic Response | 4 | 2020 | 378 | 0.27 | Why? |
| DNA, Viral | 7 | 2018 | 2521 | 0.27 | Why? |
| Pyrrolidines | 2 | 2018 | 558 | 0.26 | Why? |
| Drug Utilization | 2 | 2018 | 619 | 0.24 | Why? |
| Anti-Retroviral Agents | 4 | 2018 | 1099 | 0.24 | Why? |
| Lamivudine | 3 | 2018 | 210 | 0.23 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2021 | 116 | 0.19 | Why? |
| Hepatic Encephalopathy | 1 | 2019 | 88 | 0.19 | Why? |
| Bullying | 1 | 2020 | 98 | 0.19 | Why? |
| Immunization, Passive | 5 | 2021 | 10067 | 0.19 | Why? |
| Lymphoma, B-Cell | 1 | 2021 | 166 | 0.19 | Why? |
| Hepacivirus | 5 | 2020 | 1509 | 0.19 | Why? |
| Valine | 2 | 2018 | 359 | 0.19 | Why? |
| Teas, Herbal | 1 | 2017 | 4 | 0.18 | Why? |
| Mass Screening | 2 | 2019 | 8005 | 0.18 | Why? |
| Interferon beta-1a | 1 | 2021 | 316 | 0.18 | Why? |
| Esophageal and Gastric Varices | 1 | 2019 | 117 | 0.18 | Why? |
| Quinoxalines | 1 | 2018 | 95 | 0.17 | Why? |
| France | 3 | 2020 | 12074 | 0.17 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2021 | 403 | 0.17 | Why? |
| Chlamydia trachomatis | 1 | 2019 | 172 | 0.17 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.17 | Why? |
| Synthetic Biology | 1 | 2017 | 99 | 0.17 | Why? |
| Hepatitis Delta Virus | 1 | 2017 | 54 | 0.17 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Urinalysis | 1 | 2019 | 218 | 0.16 | Why? |
| Carbamates | 2 | 2018 | 485 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| Microfluidics | 1 | 2017 | 171 | 0.15 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.15 | Why? |
| Blood Specimen Collection | 1 | 2020 | 387 | 0.15 | Why? |
| Cameroon | 1 | 2017 | 464 | 0.15 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2018 | 260 | 0.15 | Why? |
| Blood Component Transfusion | 1 | 2020 | 740 | 0.15 | Why? |
| Dried Blood Spot Testing | 1 | 2018 | 383 | 0.14 | Why? |
| Lab-On-A-Chip Devices | 1 | 2017 | 411 | 0.13 | Why? |
| Protein Precursors | 1 | 2017 | 425 | 0.13 | Why? |
| Humans | 48 | 2021 | 930598 | 0.13 | Why? |
| Mutation | 5 | 2021 | 12376 | 0.13 | Why? |
| Adult | 22 | 2021 | 244371 | 0.13 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.13 | Why? |
| Blood Chemical Analysis | 1 | 2017 | 541 | 0.12 | Why? |
| Sulfonamides | 2 | 2018 | 1294 | 0.12 | Why? |
| Female | 25 | 2021 | 380317 | 0.12 | Why? |
| Opiate Substitution Treatment | 1 | 2018 | 613 | 0.12 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.11 | Why? |
| Male | 25 | 2021 | 367725 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Nanotechnology | 1 | 2017 | 821 | 0.11 | Why? |
| HIV | 4 | 2018 | 1116 | 0.11 | Why? |
| Blood Transfusion | 1 | 2020 | 1399 | 0.11 | Why? |
| RNA | 1 | 2018 | 1278 | 0.11 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1573 | 0.11 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 6 | 2021 | 9335 | 0.11 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.10 | Why? |
| Viral Load | 4 | 2021 | 15850 | 0.10 | Why? |
| Metabolic Syndrome | 1 | 2017 | 810 | 0.10 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.10 | Why? |
| Kinetics | 1 | 2017 | 3238 | 0.09 | Why? |
| Ritonavir | 2 | 2021 | 4212 | 0.09 | Why? |
| Cote d'Ivoire | 2 | 2018 | 115 | 0.09 | Why? |
| ROC Curve | 2 | 2017 | 6024 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.08 | Why? |
| Immunotherapy | 1 | 2021 | 2421 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2020 | 2105 | 0.08 | Why? |
| Seroconversion | 1 | 2017 | 2515 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Africa, Western | 2 | 2018 | 363 | 0.08 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.08 | Why? |
| HIV-1 | 5 | 2021 | 3365 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Genotype | 4 | 2018 | 4697 | 0.08 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2020 | 1897 | 0.07 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.07 | Why? |
| Aged | 7 | 2021 | 215776 | 0.07 | Why? |
| Africa South of the Sahara | 2 | 2020 | 1335 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.07 | Why? |
| Prospective Studies | 6 | 2018 | 43301 | 0.07 | Why? |
| Paris | 2 | 2019 | 1287 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.07 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.07 | Why? |
| Interferon Type I | 1 | 2017 | 2789 | 0.07 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.06 | Why? |
| Biosensing Techniques | 1 | 2017 | 2116 | 0.06 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.06 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Serologic Tests | 1 | 2017 | 4359 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.06 | Why? |
| Swine | 2 | 2021 | 3352 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2018 | 10017 | 0.06 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.06 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Antigens, CD20 | 1 | 2021 | 105 | 0.05 | Why? |
| Hepatorenal Syndrome | 1 | 2019 | 26 | 0.05 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.05 | Why? |
| Double-Blind Method | 2 | 2021 | 5988 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2019 | 7218 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.05 | Why? |
| 2-Naphthylamine | 1 | 2018 | 54 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Macrocyclic Compounds | 1 | 2018 | 78 | 0.05 | Why? |
| Uracil | 1 | 2018 | 101 | 0.05 | Why? |
| Lactams, Macrocyclic | 1 | 2018 | 130 | 0.05 | Why? |
| Hepatitis B Core Antigens | 1 | 2018 | 76 | 0.04 | Why? |
| Anilides | 1 | 2018 | 105 | 0.04 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.04 | Why? |
| Injections | 1 | 2018 | 237 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2021 | 801 | 0.04 | Why? |
| Organophosphonates | 1 | 2018 | 85 | 0.04 | Why? |
| Elasticity Imaging Techniques | 1 | 2019 | 194 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Drug Resistance, Neoplasm | 1 | 2021 | 447 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Guanine | 1 | 2018 | 146 | 0.04 | Why? |
| Hepatitis D | 1 | 2017 | 48 | 0.04 | Why? |
| Coffee | 1 | 2017 | 79 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Codon | 1 | 2017 | 287 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Proline | 1 | 2018 | 345 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.04 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2019 | 53120 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Immunologic Tests | 1 | 2018 | 445 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Drug Users | 1 | 2018 | 234 | 0.04 | Why? |
| Macrophage Activation | 1 | 2017 | 315 | 0.04 | Why? |
| Adenine | 1 | 2018 | 463 | 0.04 | Why? |
| Mutation Rate | 1 | 2017 | 382 | 0.04 | Why? |
| Blood Safety | 1 | 2020 | 459 | 0.04 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.03 | Why? |
| HIV Protease Inhibitors | 1 | 2017 | 434 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Liver | 2 | 2019 | 4007 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Sexual Partners | 1 | 2019 | 612 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Vietnam | 1 | 2018 | 1665 | 0.03 | Why? |
| Platelet Count | 1 | 2019 | 1381 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2019 | 1329 | 0.03 | Why? |
| Polyethylene Glycols | 1 | 2018 | 574 | 0.03 | Why? |
| Rituximab | 1 | 2021 | 1096 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.03 | Why? |
| Europe | 2 | 2018 | 12702 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.03 | Why? |
| Analgesics, Opioid | 1 | 2020 | 1070 | 0.03 | Why? |
| Interferon-alpha | 1 | 2018 | 1442 | 0.02 | Why? |
| Sexual Behavior | 1 | 2019 | 1322 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Continuity of Patient Care | 1 | 2018 | 1574 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| Ambulatory Care Facilities | 1 | 2019 | 2063 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.02 | Why? |
| Animals | 3 | 2021 | 78931 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.02 | Why? |
| Cohort Studies | 2 | 2017 | 36005 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.01 | Why? |
| Liver Transplantation | 1 | 2017 | 2864 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
Lacombe's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(227)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_